News | October 18, 2023
Syngene Q2 FY23-24 revenue from operations up 18.5% to Rs 910 Cr
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Profit after tax (before exceptional items) up 23% to Rs 215 crores
He has 37 years of experience in API Intermediaries, Pharma and Chemicals industr
He will be responsible for leading all the activities related to the Research & Development (Formulations) Division of the company
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
The composition of ORAAL is protected by a granted patent in India until November 2033
India confronts alarming rates of eye disorders, propelling the urgency of eyecare awareness
Tele-MANAS has counseled more than 3,50,000 people till date and currently provides counseling to 2000 people through 44 Tele Manas Cells
Biocon will be responsible for obtaining regulatory approval for Liraglutide, and thereafter, for the manufacture and supply of the product in the Canadian market
The discoveries by the two Nobel Laureates were critical for developing effective mRNA vaccines against COVID-19
Subscribe To Our Newsletter & Stay Updated
